Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia
- 31 December 1991
- journal article
- clinical trial
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 1 (4) , 541-548
- https://doi.org/10.1016/0924-977x(91)90008-i
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeysProgress in Neuro-Psychopharmacology and Biological Psychiatry, 1990
- Behavioural effects of dopamine D-1 and D-2 receptor agonists in monkeys previously treated with haloperidolEuropean Journal of Pharmacology, 1988
- Tardive dyskinesiaActa Psychiatrica Scandinavica, 1988
- Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesisNature, 1984
- Cis(Z)‐clopenthixol and haloperidol in chronic schizophrenic patients ‐ a double‐blind clinical multicentre investigationActa Psychiatrica Scandinavica, 1981
- Specific high-performance liquid chromatographic method for estimation of the cis(Z)- and trans(E)-isomers of clopenthixol and a N-dealkyl metaboliteJournal of Chromatography B: Biomedical Sciences and Applications, 1980
- A monitoring test for the liability of neuroleptic drugs to induce tardive dyskinesiaPsychopharmacology, 1979
- Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapinePsychopharmacology, 1978
- Changes in dopamine synthesis rate in the supersensitivity phase after treatment with a single dose of neurolepticsPsychopharmacology, 1977
- The Pharmacology of Tardive DyskinesiasAmerican Journal of Psychiatry, 1973